Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 4/20 | 0.46 |
| ▸ | MC4R | P32245 | 2/20 | 0.46 |
| ▸ | MC1R | Q01726 | 2/20 | 0.46 |
| ▸ | MC3R | P41968 | 1/20 | 0.46 |
| ▸ | FASN | P49327 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | F12 | P00748 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | CFD | P00746 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1383286 | 0.82 | P2RX7 (0.46) | P2RX7MC4RMC1RMC3REPHX2 | |
| SCHEMBL4034605 | 0.78 | ALDH1A1 (0.48) | P2RX7MC4RMC3RF12LMNA | |
| SCHEMBL1381487 | 0.77 | F12 (0.40) | MC4RMC3RF12LMNA | |
| SCHEMBL4032376 | 0.70 | ALDH1A1 (0.53) | CNR1LMNA | |
| SCHEMBL4944506 | 0.69 | P2RX7 (0.46) | P2RX7MC4RMC1RMC3REPHX2 | |
| SCHEMBL4944503 | 0.69 | P2RX7 (0.46) | P2RX7MC4RMC1RMC3REPHX2 | |
| SCHEMBL3681344 | 0.67 | POLB (0.58) | P2RX7MC4RMC1RMC3RPOLB | |
| SCHEMBL30946666 | 0.67 | P2RX7 (0.52) | P2RX7MC4RMC1RMC3REPHX2 | |
| SCHEMBL3573621 | 0.67 | FKBP1A (0.68) | POLB | |
| SCHEMBL6701308 | 0.65 | KDM4E (0.61) | P2RX7MC4RMC1RMC3REPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1592389-B1 | PIPERAZINE-2-CARBOXAMIDE DERIVATIVES | SERONO LAB (CH) | 2009-04-22 | — | — | EP | claimed |
| US-20070142391-A1 | Piperazine-2-carboxamide derivatives | MERCK SERONO SA (CH) | 2007-06-21 | — | — | US | claimed |
| US-8404690-B2 | Piperazine-2-carboxamide derivatives | MERCK SERONO SA (CH) | 2013-03-26 | — | — | US | disclosed |
| EP-1592389-B1 | PIPERAZINE-2-CARBOXAMIDE DERIVATIVES | SERONO LAB (CH) | 2009-04-22 | — | — | EP | disclosed |
| US-20070142391-A1 | Piperazine-2-carboxamide derivatives | MERCK SERONO SA (CH) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142391-A1 | Piperazine-2-carboxamide derivatives | P2RX5, P2RX2, NPY5R | P2RX7 31/4885CNR1 18/4885MC4R 2182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.